COVCovivio
51.45EUR+0.10%Mkt Cap: 6.20B $P/E: 8.77

Covivio is drawing on its history of partnership, its property expertise and its European culture, Covivio is shaping today's user experience and designing the city of tomorrow. As a leading property player operating pri…

HeadlineSourceTime
This week
Zonebourse
Zonebourse
boursorama.com
Older
Idéal Investisseur
Boursier.com
Boursorama
Boursorama
Zonebourse Suisse
covivio.eu
Orange Actualités
Idéal Investisseur
Zonebourse Suisse
Boursorama
Boursorama
covivio.eu
LL'Agefi
Idéal Investisseur
Boursier.com
covivio.eu
covivio.eu
BBusiness Immo
Covivio takes over Crowne Plaza Brussels Airport hotel management

Effective as of 1 May, the new arrangement will see Covivio operate the hotel directly through a franchise agreement with IHG.

Hotel Management Network
GL Events Valuation in Focus After Strong 61.7% Year-to-Date Rally

Thinking about what to do with your GL Events shares? Whether you are sizing up an entry point or reassessing your position after a strong rally, now is a great time to take stock of what is really happening beneath the surface. GL Events is one of those names where, if you had blinked a year ago, you might have missed some serious upside. Over the past five years, the stock has delivered a remarkable 219.9% return, and it is up 103.9% over three years alone. Even with a recent pullback of...

Simply Wall St.
Heineken’s Strongbow adds NaviLens levels to packaging

The cider brand has added a high-contrast NaviLens QR code to its cans.

Packaging Gateway
3 firms to lay off hundreds of North Jersey-based employees

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

The Bergen Record
Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Reuters